Europe's critical supply chains, particularly for generic and biosimilar drugs, are highly vulnerable due to a focus on cost reduction over resilience. While leaders recognize the issue, translating this awareness into action remains a challenge. The majority of essential medicines and their key starting materials are imported from China and India, as European manufacturing has been driven down by low-margin pricing. The COVID-19 pandemic exposed these weaknesses, and while temporary solutions were found, the current geopolitical climate and rising costs necessitate a reassessment of supply chain strategies to ensure future security and affordability. AI
RANK_REASON Article discusses industry trends and challenges without announcing a specific new product, research, or policy.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
